stuart.mccully, Author at rwr-regs

Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisation
Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisation

2023, RWE 101

Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisation

RWE 101 – Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisation

De-identification and pseudo-anonymization are two commonly used techniques for protecting personal information in real world evidence (RWE) studies.

De-identification involves removing or obscuring any personal identifiers, such as names, addresses, and social security numbers, from a dataset. The goal is to make it impossible to identify individuals in the dataset. However, de-identified data can still potentially be re-identified if combined with other data sources or through statistical analysis.

Pseudo-anonymization involves replacing personal identifiers with a unique identifier, or code, that cannot be traced back to the individual without access to a separate database. This technique provides an additional layer of protection as the original personal identifiers are not included in the dataset. However, there is still a risk that individuals can be re-identified if the codes are compromised or if the separate database is breached.

In the context of RWE, both de-identification and pseudo-anonymization can be effective in protecting personal information. The choice of technique will depend on the level of risk associated with re-identification and the specific requirements of the study. For example, if the dataset contains sensitive information or the risk of re-identification is high, pseudo-anonymization may be preferred. If the risk of re-identification is low and the dataset does not contain sensitive information, de-identification may be sufficient.

It is important to note that neither de-identification nor pseudo-anonymization can guarantee complete protection of personal information. Additional measures, such as access controls and data use agreements, may be necessary to further reduce the risk of re-identification and protect the privacy of individuals in RWE studies.

Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisationstuart.mccully2023-08-07T22:50:09+00:00

Real World Evidence (RWE) 101 – Data Tokenization
Real World Evidence (RWE) 101 – Data Tokenization

2023, RWE 101

Real World Evidence (RWE) 101 – Data Tokenization

RWE 101 – 4 Potential Uses for Improving Drug Development

Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.

Some of the opportunities of real world evidence in drug development include:

1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.

In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.

Real World Evidence (RWE) 101 – Data Tokenizationstuart.mccully2023-08-07T22:48:59+00:00

Real World Evidence (RWE) 101 – Primary Data versus Secondary Data
Real World Evidence (RWE) 101 – Primary Data versus Secondary Data

2023, RWE 101

Real World Evidence (RWE) 101 – Primary Data versus Secondary Data

RWE 101 – Primary Data versus Secondary Data

Primary data and secondary data are two types of data used in research. The main difference between the two is that primary data is collected directly from the source, while secondary data is collected from sources that have already collected the data.

Primary data is original data that is collected for a specific research project. This type of data can be collected through various methods, including surveys, interviews, observations, and experiments. Primary data is collected with a specific research objective in mind, and the data is usually more focused and targeted than secondary data.

On the other hand, secondary data is data that has already been collected by someone else for a different purpose. This type of data can be collected from a wide variety of sources, including healthcare organisations, government agencies, academic institutions, and commercial organizations. Secondary data can be used to supplement primary data or to answer research questions that are not directly related to the original research objective.

There are advantages and disadvantages to both types of data. Primary data is more likely to be accurate and relevant to the specific research question being studied, but it can also be more time-consuming and expensive to collect. Secondary data is generally less expensive and easier to access, but it may not be as accurate or relevant to the specific research question being studied.

In general, researchers will use a combination of primary and secondary data to address their research questions and achieve their research objectives

Real World Evidence (RWE) 101 – Primary Data versus Secondary Datastuart.mccully2023-08-07T22:47:38+00:00

RWE 101 – Secondary Use of Existing Data
RWE 101 – Secondary Use of Existing Data

RWE 101, Secondary Use of Existing Data

RWE 101 – Secondary Use of Existing Data

Secondary use of existing data refers to the practice of analyzing data that was collected for a different purpose than the current research question. This approach is becoming increasingly popular in real-world research because of the large amounts of data that are available through various sources, such as electronic health records, administrative databases, and social media.

In many cases, secondary data analysis can provide valuable insights and answer research questions that would otherwise be difficult or impossible to answer with primary data collection. For example, researchers can use existing data to study disease trends, evaluate the effectiveness of health interventions, and identify risk factors for various health outcomes.

Secondary data analysis can also be more cost-effective than primary data collection, as the data has already been collected and often comes at a lower cost than conducting a new study. Additionally, secondary data analysis can allow researchers to study topics that may not have been feasible to study with primary data collection due to ethical or practical limitations.

However, there are also potential limitations to secondary data analysis, such as the lack of control over the quality and accuracy of the data, and the potential for biases and confounding factors that were not accounted for in the original data collection. Therefore, researchers must carefully evaluate the suitability of existing data for their research question and take steps to address any limitations or potential biases in the data.

RWE 101 – Secondary Use of Existing Datastuart.mccully2023-08-07T22:46:24+00:00

RWE 101 – Why is there so much excitement about the use of AI in the context of real world evidence?
RWE 101 – Why is there so much excitement about the use of AI in the context of real world evidence?

RWE 101

RWE 101 – Why is there so much excitement about the use of AI in the context of real world evidence?

The use of Artificial Intelligence (AI) in the context of Real World Evidence (RWE) is generating excitement because it has the potential to transform the way healthcare is delivered and improve patient outcomes. RWE refers to data collected outside of the traditional clinical trial setting, such as electronic health records, claims data, and patient-generated data. This data provides valuable insights into how drugs and medical devices perform in real-world settings and how they impact patient health.

AI has the ability to rapidly analyze large volumes of complex data from multiple sources and identify patterns and insights that can help healthcare providers make better treatment decisions. For example, AI can help identify patient populations who may benefit most from a particular treatment, or it can help identify adverse events associated with a medication or medical device that may not have been detected in clinical trials.

The use of AI in RWE can also lead to cost savings by identifying more efficient and effective treatment options, reducing the need for trial-and-error treatments, and avoiding unnecessary procedures and tests.

Overall, the excitement surrounding the use of AI in RWE is due to its potential to improve patient outcomes, enhance healthcare delivery, and reduce costs.

RWE 101 – Why is there so much excitement about the use of AI in the context of real world evidence?stuart.mccully2023-08-07T22:45:06+00:00

RWE 101 – What is the Difference Between an IRB and a REC?
RWE 101 – What is the Difference Between an IRB and a REC?

RWE 101

RWE 101 – What is the Difference Between an IRB and a REC?

An Institutional Review Board (IRB) and a Research Ethics Committee (REC) are two different types of bodies that are responsible for ensuring that research involving human subjects is conducted in an ethical and responsible manner. While the terms are often used interchangeably, there are some differences between an IRB and a REC.

In the United States, an IRB is a committee that is established by an institution, such as a university or hospital, to review and approve research protocols that involve human subjects. The IRB is responsible for ensuring that the study is designed and conducted in an ethical manner, that the risks to participants are minimized, and that the potential benefits of the study outweigh any potential harms. The IRB also monitors ongoing studies to ensure that they continue to meet ethical and safety standards.

In other countries, such as the United Kingdom, a Research Ethics Committee (REC) may have a similar role to an IRB. RECs are independent committees that review research proposals to ensure that they meet ethical and legal requirements, and that they are designed in a way that respects the rights and welfare of human participants. RECs may also provide ongoing monitoring and review of ongoing studies.

While there are some differences in the way that IRBs and RECs are structured and operate, their overall purpose is the same: to ensure that research involving human subjects is conducted in an ethical and responsible manner. Both IRBs and RECs may require researchers to submit detailed study protocols and obtain informed consent from study participants, and both may monitor ongoing studies to ensure that they continue to meet ethical and safety standards.

RWE 101 – What is the Difference Between an IRB and a REC?stuart.mccully2023-08-07T22:43:57+00:00

RWE 101 – Do I Need IRB Approval for My Observational Study?
RWE 101 – Do I Need IRB Approval for My Observational Study?

RWE 101

RWE 101 – Do I Need IRB Approval for My Observational Study?

In general, observational studies that involve human subjects require Institutional Review Board (IRB) approval to ensure that the study is conducted in an ethical manner and that the rights and welfare of study participants are protected. This applies to both clinical trials and observational studies, including those using real-world evidence (RWE).

IRB approval is required because observational studies may involve the collection of personal or sensitive information from study participants, or the implementation of interventions or procedures that may pose risks to participants. IRBs review study protocols to ensure that the study design is scientifically sound, that the risks to participants are minimized, and that the potential benefits of the study outweigh any potential harms.

However, there are some exceptions to this requirement for IRB approval. For example, if the RWE study uses de-identified data and does not involve any interventions or interactions with human subjects, IRB approval may not be required. Additionally, certain types of RWE studies may be exempt from IRB review under certain circumstances, such as studies that use existing data and do not involve the collection of new data from human subjects.

It is important to note that the specific requirements for IRB approval may vary by country or region, and by the specific study design and research question. Therefore, it is important to consult with local regulations and guidelines, as well as with an IRB or ethics committee, to determine whether IRB approval is required for a specific observational study using RWE.

RWE 101 – Do I Need IRB Approval for My Observational Study?stuart.mccully2023-08-07T22:42:37+00:00

RWE 101 – The Evolution of Real World Evidence Regulations
RWE 101 – The Evolution of Real World Evidence Regulations

RWE 101

RWE 101 – The Evolution of Real World Evidence Regulations

Real-world evidence (RWE) has become an increasingly important source of data for regulatory decision-making in healthcare. The evolution of RWE regulations can be traced back to the late 1990s, when the US Food and Drug Administration (FDA) began to encourage the use of observational studies, such as registries and natural history studies, to supplement clinical trial data in the evaluation of medical products.

In 2011, the FDA launched the Sentinel Initiative, a program that uses electronic health records and other healthcare data sources to monitor the safety of medical products in real time. This initiative paved the way for the use of RWE in regulatory decision-making, and led to the development of guidelines and frameworks for the use of RWE in drug development and regulatory decision-making.

In 2016, the 21st Century Cures Act was signed into law in the US, which included provisions to support the use of RWE in regulatory decision-making. The Act directed the FDA to establish a program to evaluate the potential use of RWE to support drug approvals, and to issue guidance on the use of RWE in regulatory decision-making.

In 2018, the FDA issued its first guidance on the use of RWE to support drug approvals, which outlined the types of RWE that could be used, the study designs that could be employed, and the factors that would be considered in the evaluation of RWE. The guidance also emphasized the importance of ensuring the quality and reliability of RWE, and the need for transparent reporting and validation of RWE studies.

Since then, regulatory agencies around the world have continued to develop guidelines and frameworks for the use of RWE in regulatory decision-making. For example, the European Medicines Agency (EMA) has established a framework for the use of RWE in the evaluation of medicines, which includes the use of RWE to support marketing authorizations and post-authorization safety monitoring.

Overall, the evolution of RWE regulations reflects the growing recognition of the value of real-world data in healthcare decision-making, and the need for guidelines and frameworks to ensure the quality and reliability of RWE studies.

RWE 101 – The Evolution of Real World Evidence Regulationsstuart.mccully2023-08-07T22:41:24+00:00

RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?
RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?

RWE 101

RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?

Real world evidence (RWE) is not a replacement for clinical trials. Clinical trials are considered the gold standard for assessing the safety and efficacy of medical treatments because they are designed to control for various factors that could influence the results, such as confounding variables and bias. In contrast, RWE is based on observations and data collected from real-world settings, where there may be many confounding factors that can affect the outcomes.

However, RWE can complement clinical trials by providing additional insights into the effectiveness and safety of medical treatments in real-world settings. RWE can help to identify potential safety concerns, as well as provide information about the effectiveness of treatments in patient populations that may not have been included in the clinical trials.

Furthermore, RWE can also help to inform the design of future clinical trials by providing information about the natural history of diseases and the characteristics of patient populations. RWE can also help to identify potential subgroups of patients that may benefit more from certain treatments.

In summary, RWE is not a replacement for clinical trials, but it can provide valuable complementary information to help inform clinical decision-making and optimize the use of medical treatments.

RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?stuart.mccully2023-08-07T22:40:10+00:00

RWE 101 – How Robust is RWE?
RWE 101 – How Robust is RWE?

RWE 101

RWE 101 – How Robust is RWE?

Real world evidence (RWE) is evidence that is collected outside of traditional randomized controlled trials (RCTs), such as observational studies and patient registries. While RWE can provide valuable insights into the effectiveness and safety of medical treatments in real-world settings, its robustness can vary depending on a number of factors.

One important factor to consider is the quality of the data sources used to generate RWE. RWE that is based on high-quality, comprehensive data sources such as electronic health records (EHRs) or administrative claims databases may be more robust than RWE that is based on smaller or less comprehensive data sources. Additionally, RWE that is collected using standardized protocols and methods may be more robust than RWE that is collected in an ad hoc or inconsistent manner.

Another important factor to consider is the potential for bias in RWE. Observational studies and other forms of RWE are subject to a number of biases, such as selection bias and confounding, that can affect the accuracy of their findings. While methods such as propensity score matching and sensitivity analyses can help to mitigate these biases, it is important to be aware of their potential impact on the robustness of RWE.

Ultimately, the robustness of RWE will depend on a number of factors, including the quality of the data sources, the methods used to collect and analyze the data, and the potential for bias. While RWE can provide valuable insights into the real-world effectiveness and safety of medical treatments, it should be interpreted with caution and in the context of other available evidence.

RWE 101 – How Robust is RWE?stuart.mccully2023-08-07T22:39:01+00:00

About stuart.mccully

Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisation

RWE 101 – Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisation

Real World Evidence (RWE) 101 – Data Tokenization

RWE 101 – 4 Potential Uses for Improving Drug Development

Real World Evidence (RWE) 101 – Primary Data versus Secondary Data

RWE 101 – Primary Data versus Secondary Data

RWE 101 – Secondary Use of Existing Data

RWE 101 – Secondary Use of Existing Data

RWE 101 – Why is there so much excitement about the use of AI in the context of real world evidence?

RWE 101 – Why is there so much excitement about the use of AI in the context of real world evidence?

RWE 101 – What is the Difference Between an IRB and a REC?

RWE 101 – What is the Difference Between an IRB and a REC?

RWE 101 – Do I Need IRB Approval for My Observational Study?

RWE 101 – Do I Need IRB Approval for My Observational Study?

RWE 101 – The Evolution of Real World Evidence Regulations

RWE 101 – The Evolution of Real World Evidence Regulations

RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?

RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?

RWE 101 – How Robust is RWE?

RWE 101 – How Robust is RWE?

Help

Follow Us

Legal Info

Cookies

About stuart.mccully

RWE 101 – Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisation

Share this story...

RWE 101 – 4 Potential Uses for Improving Drug Development

Share this story...

RWE 101 – Primary Data versus Secondary Data

Share this story...

RWE 101 – Secondary Use of Existing Data

Share this story...

RWE 101 – Why is there so much excitement about the use of AI in the context of real world evidence?

Share this story...

RWE 101 – What is the Difference Between an IRB and a REC?

Share this story...

RWE 101 – Do I Need IRB Approval for My Observational Study?

Share this story...

RWE 101 – The Evolution of Real World Evidence Regulations

Share this story...

RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?

Share this story...

RWE 101 – How Robust is RWE?

Share this story...

Help

Follow Us

Legal Info

Cookies